Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down - Here's Why

Key Points

• Ono Pharmaceutical's shares gapped down from $11.50 to $10.50 before market opening, with a last traded volume of 288 shares.
• The company reported a quarterly earnings miss of $0.26 per share, falling short of consensus estimates of $0.34, despite achieving revenues of $886.27 million.
• Ono Pharmaceutical has a market capitalization of $5.35 billion and a price-to-earnings ratio of 18.39, indicating relatively stable financial metrics.

Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $11.50, but opened at $10.50. Ono Pharmaceutical shares last traded at $10.50, with a volume of 288 shares changing hands.

Ono Pharmaceutical Stock Performance

The stock has a market cap of $5.74 billion, a price-to-earnings ratio of 19.71 and a beta of 0.51. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.07 and a quick ratio of 2.56. The firm has a fifty day moving average of $10.69 and a 200 day moving average of $10.76.

Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.34 by ($0.08). Ono Pharmaceutical had a net margin of 8.75% and a return on equity of 5.49%. The company had revenue of $886.27 million during the quarter, compared to analysts' expectations of $827.29 million.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.